Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2024-08-29 00:00:00 ET · period of report 2024-08-27 · accession 0001610520-24-000151 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-08-29 | 2024-08-27 | NDRA | UBS Group AG | 10% | P - Purchase | $0.55 | +3,715 | 146.0K | +3% | +$2,043 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-27 | P | A | 3,715 | $0.55 | 146,012 | I By Subsidiary | — | — | (F1) This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group |